

February 16, 2024

Dear Valued Client,

HNL Lab Medicine strives to offer the most up to date testing while remaining steadfast in our dedication to compliance. Recent internal auditing of drug screen testing has shown ordering patterns that are not consistent with Local Coverage Determinations (LCD).

LCD - Controlled Substance Monitoring and Drugs of Abuse Testing (L35006) (cms.gov)

HNL Lab Medicine is making the following recommendations regarding our Clinical and Pain Management Drug Test offerings to ensure compliance:

- Medical Necessity A patient's medical record must include reason for order, frequency of testing, and results discussion.
- Blanket Orders Identical orders for all patients without individualized decision making at every visit is a non-covered service and discouraged.
- **Direct Definitive Testing** may NOT be medically necessary for analytes such as Fentanyl, and Buprenorphine. Avoid ordering definitive testing when presumptive is available and appropriate.

Tip! Test Code, UDSE – Includes presumptive testing for 15 analytes including Fentanyl, Buprenorphine, and Heroin metabolite which may omit the need for additional definitive testing. All analytes in UDSE are available as a single order.

Important Pain Management Test Menu Updates: EFFECTIVE MARCH 12, 2024

- Pain Management Supplemental Profile (test code: PMPE) will be INACTIVATED
 - Includes direct definitive testing for Fentanyl, Tramadol, Tapentadol, Meperidine, and Carisoprodol
 - Pain Management statistics have shown the positivity rates for Carisoprodol and Meperidine have been 1.7% and 0% respectively for the last year
 - · All analytes available as a single order after March 12. Please order necessary tests individually
- Pain Management Basic Profile, Urine (test code: PMBP) will INCLUDE presumptive screening for Fentanyl testing of
 positive and unexpected negative screening results
 - This adjustment is crucial for compliance reasons and coincides with the inactivation of the PMPE battery
 - See the attached Special Advisory Lab-Link for additional information

If you have any questions or require further clarification, please contact **compliance@hnl.com**.

Sincerely,

HNL Lab Medicine



Special Advisory | LAB-LINK

New and updated laboratory testing information

February 16, 2024

Important Update: Pain Management Testing Profiles

Pain Management Supplemental Profile PMPE					
Effective Date	Tuesday, March, 12, 2024				
Test Name	Pain Management Supplemental Profile				
Test Code	PMPE				
	 The Pain Management Supplemental Profile (test code: PMPE) will be inactivated Includes direct definitive testing for Fentanyl, Tramadol, Tapentadol, Meperidine, and Carisoprodol Pain Management statistics have shown the positivity rates for Carisoprodol and Meperidine have been 1.7% and 0% respectively for the last year All analytes available as a single order after March 12. Please order necessary tests 				
Description of Change	Test Code PPCAR PPMEP PPTAP PPTRA	Test Name Pain Management Carisoprodol/Meprobamate, Quantitative, Urine Pain Management Meperidine/Normeperidine, Quantitative, Urine Pain Management Tapentadol, Quantitative, Urine Pain Management Tramadol, Quantitative, Urine			

Pain Managemer	nt Basic Profile, Urine					
Effective Date	Tuesday, March, 12, 2024					
Test Name	Pain Management Basic Profile, Urine					
Test Code	PMBP					
	The Pain Management Basic Profile (test code: PMBP) will now include presumptive screening for Fentanyl.					
Description of Change	Presumptive screening for the following analytes with reflex of positive and unexpected negative results for the PMBP Profile include:					
	Amphetamines	Buprenorphine	Fentanyl	Methadone		
	Barbiturates	Cannabinoids	Opiates	Phencyclidine		
	Benzodiazepines	Cocaine metabolite	Oxycodone	Validity testing		

Pain Managemer	nt Opiate, Quantitative, Urine PPOPI				
Effective Date	Tuesday, March, 12, 2024				
Test Name	Pain Management Opiate, Quantitative, Urine				
Test Code	PPOPI				
	Oxycodone, Oxymorphone, and Noroxycodone will be removed and tested separately. See NEW Test Order PPOXY				
Description of Change	Pain Management Opiate Screen will reflex to a Pain Management Opiate, Quantitative, Urine (PPOPI).				
	This test will provide definitive testing (confirmation/quantitation) for the following analytes:				
	Codeine • Morphine • 6MAM • Hydrocodone • Hydromorphone • Norhydrocodone				

Pain Managemer	nt Oxycodone, Quantitative, Urine	PPOXY	
Effective Date	Tuesday, March, 12, 2024		
Test Name	Pain Management Oxycodone, Quantitative, Urine		
Test Code	PPOXY		
Description of Change	New Test Order – Pain Management Oxycodone Screen will reflex to a Pain Management Oxycodone, Quantitative, Urine (PPOXY).		
	This test will provide definitive testing (confirmation/quantitation) for the following analytes: Oxycodone • Oxymorphone • Noroxycodone		

Additional Information

If you have additional questions regarding these tests, please contact Technical Support between the hours of 8 a.m. and 4:30 p.m. For general questions, Customer Care is available to assist at any time.

Technical Support/Customer Care

Call 877-402-4221

02022024_v7